
Join to view full profile
44 Binney Streetd1b30Danafarber Cancer InstituteBoston, MA 02115
Phone+1 617-632-5946
Fax+1 617-632-5168
Dr. Cutler is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
McGill University Faculty of MedicineClass of 1996
McGill University Faculty of MedicineMD, Medicine, 1991 - 1995
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2028
VT State Medical License 2023 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017
Publications & Presentations
PubMed
- 1 citationsIs It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?Amar H Kelkar, Gregory A Abel, Corey S Cutler, Stephanie J Lee, Robert J Soiffer
Journal of Clinical Oncology. 2026-05-20 - Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.Oren Pasvolsky, Shai Shimony, Rima M Saliba, Curtis Marcoux, Celina Ledesma
American Journal of Hematology. 2026-01-01 - Medication Adherence in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Hermioni L Amonoo, Emma D Wolfe, Emma P Keane, Isabella S Larizza, Annabella C Boardman
Cancers. 2025-08-01
Abstracts/Posters
- Graft Failure after Haploidentical Hematopoietic Stem Cell TransplantationCorey Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Development of HHV-6-Specific Immunity after Cord Blood Transplantation inCorey S. Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced IntensityCorey Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- 'The Evolving Treatment Landscape for Patients with GvHD: More Options, More61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- 'Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and60th American Society of Hematology Annual Meeting - 11/30/2018
- Highlights of ASH® San Diego, CAAmerican Society of Hematology (ASH), San Diego, California - 1/18/2013
Press Mentions
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Recognized for Exceptional Outcomes in Donor Stem Cell TransplantsDecember 17th, 2025
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025
FDA Approves Treatment for Chronic Graft Versus Host DiseaseSeptember 6th, 2024
Grant Support
- Mechanisms and Therapy of Chronic Graft-vs.-Host DiseaseDANA-FARBER CANCER INST2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: